Aspira Women's Health Inc expected to post a loss of 33 cents a share - Earnings Preview

Aspira Women's Health

07/05/2024 12:46

* Aspira Women's Health Inc  AWH.OQ   AWH.O  is expected
to show a
rise in quarterly revenue when it reports  results on May 9
(estimated) for the period ending March 31 2024
    * The Austin Texas-based  company is expected to report a
10.7% increase in revenue to $2.565 million from $2.32 million a
year ago, according to the mean estimate from 4 analysts, based
on LSEG data.
    * ​LSEG's mean analyst estimate for Aspira Women's Health
Inc is
for a loss of 33 cents per share. 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Aspira
Women's
Health Inc is $5.25​, above​ its last closing price of $3.21.
​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Dec. 31 2023  -0.39       -0.45      -0.30     Beat    33
 Sep. 30 2023  -0.45       -0.51      -0.48     Beat    5.4
 Jun. 30 2023  -0.55       -0.55      -0.28     Beat    49.1​
 Mar. 31 2023  -0.75       -0.75      -0.73     Beat    2.7
 ​​Dec.        -1.05       -0.97      -0.60     Beat    38.5
 31 2022                                                
 Sep. 30 2022  -0.98       -0.97      -1.20     Missed  -23.1​
 Jan. 1 0001   -1.05       -1.05      -1.05     Met     0
 Jan. 1 0001   -1.20       -1.20      -1.20     Met     0
 This summary was machine generated May 7 at 11:46 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)